SCHEMBL15765122

SCHEMBL15765122

CC(C)(C)OC(=O)NCC1Cc2c(-c3ccccc3C(=O)N3CCOCC3)ccc(Cl)c2O1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ PIK3R2 O00459 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PIK3R5 Q8WYR1 1/20 0.36
▸ PIK3R3 Q92569 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ EPAS1 Q99814 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17961492 0.88 KDM4E (0.42) KDM4EALDH1A1KMT2AEPAS1TSHR
SCHEMBL15765177 0.88 NAMPT (0.35) NAMPTDRD2
SCHEMBL17974462 0.84 KDM4E (0.45) KDM4EALDH1A1NPSR1KMT2APKM
SCHEMBL15758729 0.82 KDM4E (0.45) KDM4EALDH1A1NPSR1KMT2AEPAS1
SCHEMBL15758046 0.75 CNR1 (0.34) KDM4EALDH1A1HPGDLMNATSHR
SCHEMBL17961494 0.74 KDM4E (0.42) KDM4EALDH1A1KMT2AEPAS1TSHR
SCHEMBL15764957 0.74 RORC (0.40) KDM4EHPGDNAMPTKMT2ALMNA
SCHEMBL15765143 0.74 HPGD (0.44) HPGDNPSR1PKMTSHR
SCHEMBL17987855 0.73 CECR2 (0.34) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL15764954 0.72 F10 (0.35) NAMPTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 — — US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 — — US disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 KDM4E 609/4885ALDH1A1 214/4885HPGD 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback